Showing results (151-160 of 352) with videos related to

Sort By:
Pageof 36
BMC Rheumatology|April 9, 2020
Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort studyDavid P Hudesman, Soumya D Chakravarty, Bruno Emond, et al.
Surgical Endoscopy|December 24, 2016
Five-year results of laparoscopic sleeve gastrectomy for the treatment of severe obesityDavid Nocca, Marcelo Loureiro, El Mehdi Skalli, et al.
Advances in Therapy|August 14, 2024
Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or AdalimumabMaryia Zhdanava, Sumesh Kachroo, Porpong Boonmak, et al.
Journal of Medical Economics|May 21, 2019
Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulantsMichael Streiff, Dejan Milentijevic, Keith R McCrae, et al.
Current Medical Research and Opinion|March 21, 2018
Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice settingCarol H Wysham, Dominic Pilon, Mike Ingham, et al.
Allergy & Rhinology (Providence, R.I.)|July 7, 2018
Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on OmalizumabAbhishek Kavati, Dominic Pilon, Benjamin Ortiz, et al.
The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists|August 26, 2010
Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney diseaseMarie-Hélène Lafeuille, Robert A Bailey, Francis Vekeman, et al.
Journal of Managed Care & Specialty Pharmacy|November 21, 2019
Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance CoverageCarmela Benson, Bruno Emond, Patrick Lefebvre, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|March 6, 2014
Burden of schizophrenia on selected comorbidity costsMarie-Hélène Lafeuille, Jason Dean, John Fastenau, et al.
Journal of Medical Economics|May 20, 2009
Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care databaseFrancis Vekeman, R Scott McKenzie, Brahim K Bookhart, et al.
Pageof 36